EFTR (eFFECTOR Therapeutics) Cash-to-Debt : 1.25 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. eFFECTOR Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 1.25.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, eFFECTOR Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for eFFECTOR Therapeutics's Cash-to-Debt or its related term are showing as below:

EFTR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.87 Med: 1.28 Max: 2.77
Current: 1.25

During the past 4 years, eFFECTOR Therapeutics's highest Cash to Debt Ratio was 2.77. The lowest was 0.87. And the median was 1.28.

EFTR's Cash-to-Debt is ranked worse than
73.19% of 1488 companies
in the Biotechnology industry
Industry Median: 7.4 vs EFTR: 1.25

eFFECTOR Therapeutics Cash-to-Debt Historical Data

The historical data trend for eFFECTOR Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

eFFECTOR Therapeutics Cash-to-Debt Chart

eFFECTOR Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

1.17

2.48

1.30

0.89

eFFECTOR Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial										0.93	1.23	0.87	0.89	1.25

Competitive Comparison of eFFECTOR Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, eFFECTOR Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

eFFECTOR Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's Cash-to-Debt falls into.

eFFECTOR Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

eFFECTOR Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	18.37	/	(20.545	+	0)
	=	0.89

eFFECTOR Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	25.383	/	(20.069	+	0.179)
	=	1.25

eFFECTOR Therapeutics (OTCPK:EFTR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

eFFECTOR Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

eFFECTOR Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (OTCPK:EFTR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075

Website

https://www.effector.com

eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).

Executives

Sr One Capital Fund I Aggregator Lp	10 percent owner	C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich	director, 10 percent owner, officer: Chief Executive Officer	499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi	officer: Chief Business Officer	628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner	officer: Chief Medical Officer	C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc	10 percent owner	2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc	10 percent owner	1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc	10 percent owner	C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c.	10 percent owner	C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c.	10 percent owner	C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr.	director, 10 percent owner	C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland	director, officer: President and Chief Executive	9050 CAMINO SANTA FE, SAN DIEGO CA 92121